Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,970 DKK | +0.79% | -2.96% | -8.58% |
Apr. 29 | Pfizer, Genmab Get Full FDA Approval for Cervical-Cancer Drug | DJ |
Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
Sales 2024 * | 19.66B 2.82B | Sales 2025 * | 23.51B 3.38B | Capitalization | 127B 18.29B |
---|---|---|---|---|---|
Net income 2024 * | 5.11B 733M | Net income 2025 * | 6.76B 970M | EV / Sales 2024 * | 5.13 x |
Net cash position 2024 * | 26.57B 3.81B | Net cash position 2025 * | 33.5B 4.81B | EV / Sales 2025 * | 3.99 x |
P/E ratio 2024 * |
25.2
x | P/E ratio 2025 * |
19.4
x | Employees | 2,204 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.87% |
Latest transcript on Genmab A/S
1 day | +0.79% | ||
1 week | -2.96% | ||
Current month | -5.47% | ||
1 month | -5.47% | ||
3 months | +2.52% | ||
6 months | -1.84% | ||
Current year | -8.58% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Director/Board Member | 73 | 03-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 63 | 15-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.64% | 192 M€ | +14.01% | ||
1.28% | 49 M€ | +6.28% | ||
1.01% | 96 M€ | -0.43% | ||
0.75% | 18 M€ | +4.31% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 1,970 | +0.79% | 124,815 |
24-04-26 | 1,954 | +2.04% | 108,599 |
24-04-25 | 1,916 | -2.87% | 157,995 |
24-04-24 | 1,972 | -1.79% | 150,555 |
24-04-23 | 2,008 | -1.08% | 131,041 |
Delayed Quote Nasdaq Copenhagen, April 29, 2024 at 10:59 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.58% | 18.15B | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B | |
-24.98% | 8.24B |
- Stock Market
- Equities
- GMAB Stock